Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Tranexamic Acid (IV)

The intervention is administered as a clear, colorless solution infusion. The dosage administered is a 1 gram intravenous (IV) push, delivered immediately before starting the Aquablation therapy. The administration of TXA occurs only once, as a single dose preoperatively.

DRUG

Placebo

Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.

Trial Locations (1)

90027

Kaiser Permanente Los Angeles Medical Center, Los Angeles

All Listed Sponsors
lead

Kaiser Permanente

OTHER